FLGT

Fulgent Genetics, Inc. (FLGT) | Rumor.io

Fulgent Genetics

FLGT

Attention (50-day avg)0%

Attention rank (50-day avg)#4,781

Bullish sentiment (50-day avg)67%

Price to earnings ratio-11.3

Market capitalization615.2M

Earnings per share-2.83

Dividend yield (TTM)—

Revenue (annual)322.7M

Net income (annual)-61.6M

Social

What share of all stock conversation is about FLGT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Feb 27

$FLGT reported Q4 2025 revenue of $83.3M, up 9% YoY, and full-year 2025 revenue of $322.7M, up 14% YoY.
The company swung to a GAAP loss in Q4 2025, but reported Non-GAAP income, and has a strong cash position of $705.5M.
Fulgent Genetics acquired a company that adds 20-30 sales reps, with no customer accounting for more than 10% of revenue, and is expecting 9% revenue growth in 2026.

Generated by AI

Sentiment

Of the messages about FLGT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	86.35% +1.65
Bearish	—	0%	0% 0	13.65% -1.65

Bullish· Nov 7

$FLGT is expected to report core revenue of over $200 million going forward, with its core business now driving the company rather than COVID-19 tests.
Fulgent Genetics is a self-funding biotech with a strong drug discovery platform, making it an attractive investment opportunity, especially considering its ability to fund its own clinical and drug research activities.
The company's insider ownership gives hope for long-term success, with insiders holding onto their shares despite market volatility.

Bearish· Feb 27

FLGT's loss of a large customer, which accounted for a quarter of their revenue, has added uncertainty to the company's future.
The company's projected non-GAAP loss for 2026 is a concern, especially given the recent loss of a major customer.
FLGT's stock is trading below its cash value and has been severely beaten down, with some investors describing the market's reaction as "absurd" and "insane".

Generated by AI

Topics

Of the messages about FLGT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Earnings	—	0%	0%	12.9%
Technical Analysis	—	100%	100%	67.45%
Analysts	—	0%	0%	9.68%
Announcements	—	0%	0%	9.97%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	0%

Earnings· Nov 7

Fulgent Genetics ($FLGT) reports Q3 revenue of $105.7 million, down 54% YoY, with core revenue growing 110% YoY.
The company guides for Q4 revenue of $60 million, down 76% YoY, and core revenue of $52 million, up 86% YoY.
Fulgent Genetics acquires Fulgent Pharma for $100 million cash and stock, a move that may signal the company's expansion into the preclinical biotech space.

Announcements· Nov 7

Fulgent Genetics ($FLGT) reported Q3 2022 financial results with revenue of $105.7 million, core revenue growth of 110% YoY, and a GAAP income of $1.7 million.
The company guided for a weaker Q4 with revenue of $60 million and core revenue of $52 million, citing a drop in covid testing to near zero.
Fulgent Genetics acquired Fulgent Pharma in a cash and stock deal valued at $100 million, gaining access to a novel nano-drug delivery platform with a US FDA drug master file.

Controversies· Oct 8

ROSEN, a top-ranked investor counsel, encourages Fulgent Genetics investors to secure counsel before an important deadline in a securities class action.
ClaimsFiler reminds investors with losses in excess of $100,000 of the lead plaintiff deadline in a class action lawsuit against Fulgent Genetics.
Fulgent Genetics shareholders are alerted to a class action lawsuit with a lead plaintiff deadline, as per ClaimsFiler.

Technical Analysis· Mar 17

$FLGT is forming an inverse head and shoulders pattern, with a large volume shelf forming around the price within the pattern, and the stock exhibited strong relative strength during the pullback.
Breaking out of the inverse head and shoulders pattern, $FLGT is showing strong volume patterns and a potential breakout from a flag, with a target of $130 if the breakout sticks.
$FLGT's relative strength is breaking above 115, with a weekly chart showing a strong momentum indicator, and a potential move back up to its previous high near $190.

Generated by AI

Community

Of the messages about FLGT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	23.3%
Newcomers	—	100%	100%	76.7%

Regulars· May 5

Fulgent Genetics reported Q1 revenue of $66.2 million, a 79% YoY decline, but core revenue of $62.7 million, a 150% YoY increase.
The company sees Q2 core revenue of $62 million, a 37% YoY increase, and FY23 core revenue of $250 million, a 38% YoY increase.
Fulgent Genetics guided FY23 non-GAAP EPS to a loss of $1.25 per share, beating consensus estimates.

Newcomers· Feb 27

The company reported a Q4 net loss and issued weak 2026 guidance, with a projected non-GAAP loss of about $1.45 per share, below market expectations.
The company's 2026 guidance was overshadowed by a major customer defection, which is expected to trigger a massive profitability reversal.
The company's Q4 revenue grew 9% year-over-year, with a solid performance in the quarter, but the forward outlook was marred by weak guidance and a projected non-GAAP loss.

Generated by AI

News

PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?

Detailed price information for Precipio Inc (PRPO-Q) from The Globe and Mail including charting and trades.

7d agoThe Globe and Mail

Fulgent Genetics (FLGT) Q2 2026 Earnings Call Transcript

Detailed price information for Fulgent Genetics Inc (FLGT-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about FLGT also mention

#	Name	Attention
1	QuidelOrtho CorporationQDEL	0%new
2	Appian Corp Class A Common StockAPPN	0%new
3	Live Oak Bancshares Inc.LOB	0%new
4	Twist Bioscience CorporationTWST	0%-0.02
5	OptimizeRx CorporationOPRX	0%0
6	Fiverr International Ltd.FVRR	0.01%+0.01
7	Futu Holdings Ltd. ADRFUTU	0%0
8	Magnite, Inc.MGNI	0.01%+0.01
9	Teladoc Health Inc.TDOC	0%+0
10	Pinterest, Inc. Class APINS	0%0

Fulgent Genetics, Inc.

Healthcare
Diagnostics & Research

Fulgent Genetics, Inc. is a healthcare diagnostics company that provides molecular testing, genetic testing, and anatomic pathology services to physicians, hospitals, and medical institutions. Its offerings cover a broad range of clinical areas, including hereditary cancer, reproductive health, oncology, gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology. The company also provides sequencing-based solutions and laboratory services designed to support clinically actionable medical decision-making. In addition to its diagnostic business, Fulgent Genetics, Inc. operates therapeutic development activities focused on cancer-related drug candidates. Headquartered in El Monte, California, the company serves customers in the United States and internationally and plays a role in combining laboratory testing, bioinformatics, and specialized pathology services within the broader precision medicine market.

Website

Location

4399 Santa Anita Avenue

El Monte, CA, 91731

United States

Social

What share of all stock conversation is about FLGT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Feb 27

$FLGT reported Q4 2025 revenue of $83.3M, up 9% YoY, and full-year 2025 revenue of $322.7M, up 14% YoY.
The company swung to a GAAP loss in Q4 2025, but reported Non-GAAP income, and has a strong cash position of $705.5M.
Fulgent Genetics acquired a company that adds 20-30 sales reps, with no customer accounting for more than 10% of revenue, and is expecting 9% revenue growth in 2026.

Generated by AI

Sentiment

Of the messages about FLGT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100% 0	86.35% +1.65
Bearish	—	0%	0% 0	13.65% -1.65

Bullish· Nov 7

$FLGT is expected to report core revenue of over $200 million going forward, with its core business now driving the company rather than COVID-19 tests.
Fulgent Genetics is a self-funding biotech with a strong drug discovery platform, making it an attractive investment opportunity, especially considering its ability to fund its own clinical and drug research activities.
The company's insider ownership gives hope for long-term success, with insiders holding onto their shares despite market volatility.

Bearish· Feb 27

FLGT's loss of a large customer, which accounted for a quarter of their revenue, has added uncertainty to the company's future.
The company's projected non-GAAP loss for 2026 is a concern, especially given the recent loss of a major customer.
FLGT's stock is trading below its cash value and has been severely beaten down, with some investors describing the market's reaction as "absurd" and "insane".

Generated by AI

Topics

Of the messages about FLGT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Earnings	—	0%	0%	12.9%
Technical Analysis	—	100%	100%	67.45%
Analysts	—	0%	0%	9.68%
Announcements	—	0%	0%	9.97%
Controversies	—	0%	0%	0%
Macro	—	0%	0%	0%

Earnings· Nov 7

Fulgent Genetics ($FLGT) reports Q3 revenue of $105.7 million, down 54% YoY, with core revenue growing 110% YoY.
The company guides for Q4 revenue of $60 million, down 76% YoY, and core revenue of $52 million, up 86% YoY.
Fulgent Genetics acquires Fulgent Pharma for $100 million cash and stock, a move that may signal the company's expansion into the preclinical biotech space.

Announcements· Nov 7

Fulgent Genetics ($FLGT) reported Q3 2022 financial results with revenue of $105.7 million, core revenue growth of 110% YoY, and a GAAP income of $1.7 million.
The company guided for a weaker Q4 with revenue of $60 million and core revenue of $52 million, citing a drop in covid testing to near zero.
Fulgent Genetics acquired Fulgent Pharma in a cash and stock deal valued at $100 million, gaining access to a novel nano-drug delivery platform with a US FDA drug master file.

Controversies· Oct 8

ROSEN, a top-ranked investor counsel, encourages Fulgent Genetics investors to secure counsel before an important deadline in a securities class action.
ClaimsFiler reminds investors with losses in excess of $100,000 of the lead plaintiff deadline in a class action lawsuit against Fulgent Genetics.
Fulgent Genetics shareholders are alerted to a class action lawsuit with a lead plaintiff deadline, as per ClaimsFiler.

Technical Analysis· Mar 17

$FLGT is forming an inverse head and shoulders pattern, with a large volume shelf forming around the price within the pattern, and the stock exhibited strong relative strength during the pullback.
Breaking out of the inverse head and shoulders pattern, $FLGT is showing strong volume patterns and a potential breakout from a flag, with a target of $130 if the breakout sticks.
$FLGT's relative strength is breaking above 115, with a weekly chart showing a strong momentum indicator, and a potential move back up to its previous high near $190.

Generated by AI

Community

Of the messages about FLGT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	23.3%
Newcomers	—	100%	100%	76.7%

Regulars· May 5

Fulgent Genetics reported Q1 revenue of $66.2 million, a 79% YoY decline, but core revenue of $62.7 million, a 150% YoY increase.
The company sees Q2 core revenue of $62 million, a 37% YoY increase, and FY23 core revenue of $250 million, a 38% YoY increase.
Fulgent Genetics guided FY23 non-GAAP EPS to a loss of $1.25 per share, beating consensus estimates.

Newcomers· Feb 27

The company reported a Q4 net loss and issued weak 2026 guidance, with a projected non-GAAP loss of about $1.45 per share, below market expectations.
The company's 2026 guidance was overshadowed by a major customer defection, which is expected to trigger a massive profitability reversal.
The company's Q4 revenue grew 9% year-over-year, with a solid performance in the quarter, but the forward outlook was marred by weak guidance and a projected non-GAAP loss.

Generated by AI

Fulgent Genetics

Social

Feb 27

Bullish· Nov 7

Bearish· Feb 27

Earnings· Nov 7

Announcements· Nov 7

Controversies· Oct 8

Technical Analysis· Mar 17

Regulars· May 5

Newcomers· Feb 27

PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?

Fulgent Genetics CSO Hanlin Gao sells $32,885 in stock

Fulgent Genetics president and COO Xie Jian sells $41,809 in stock

Fulgent Genetics CSO Gao Hanlin sells $18,691 in stock

Fulgent Genetics COO Xie Jian disposes of $23,747 in company stock

Fulgent Genetics (FLGT) Q2 2026 Earnings Call Transcript

Also Discussed

Fulgent Genetics, Inc.

Company Information

Location

PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?

Fulgent Genetics CSO Hanlin Gao sells $32,885 in stock

Fulgent Genetics president and COO Xie Jian sells $41,809 in stock

Fulgent Genetics CSO Gao Hanlin sells $18,691 in stock

Fulgent Genetics COO Xie Jian disposes of $23,747 in company stock

Fulgent Genetics (FLGT) Q2 2026 Earnings Call Transcript

Also Discussed

Social

Feb 27

Bullish· Nov 7

Bearish· Feb 27

Earnings· Nov 7

Announcements· Nov 7

Controversies· Oct 8

Technical Analysis· Mar 17

Regulars· May 5

Newcomers· Feb 27